I
IDbyDNA
The technologies that will enable nucleic acid based identification of any life form on earth
About IDbyDNA
IDbyDNA operates in the clinical metagenomics sector, providing advanced solutions for rapid pathogen detection and antibiotic resistance analysis. The company's core product, the Explify Platform, leverages next-generation sequencing technology from Illumina to offer a streamlined workflow from specimen to report within 24 hours. IDbyDNA serves a diverse range of clients, including hospital reference labs, clinical research institutions, and biopharmaceutical companies. The business model is centered around providing comprehensive metagenomic testing services and analytics, generating revenue through partnerships, service contracts, and the commercialization of specialized diagnostic tools. Recently, IDbyDNA has partnered with CareDx to develop AlloID, a tool aimed at detecting infectious diseases in organ transplant patients. The market for IDbyDNA's services includes clinical laboratories, genomic centers, and microbiology labs, focusing on enhancing diagnostic accuracy and speed. The company also supports educational initiatives through CME programs and offers a variety of resources such as webinars, podcasts, and case studies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2014
- Headquarters
- San Francisco, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 56.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jun 2022 | $0 | — | Illumina | ↗ |
| DEBTDebt | Dec 2020 | $10M | — | Horizon Technology Finance Corporation | — |
Growth signals
Latest recorded traffic for IDbyDNA is 120 monthly website visits, down 87.8% over the last three months. IDbyDNA's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Artis Ventures
Abstract Ventures
ARUP Laboratories
Genesys Capital
Series B and later1 investor entered at this stage
Horizon Technology Finance Corporation
Other known investors5 additional known investors
Illumina
University of Utah- CUCSC Upshot
Hemisphere Ventures
Hone Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about IDbyDNA on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IDbyDNA’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.